AnaptysBio climbs on arthritis drug trial data

AnaptysBio

12/02/2025 15:42

** Shares of drug developer AnaptysBio  ANAB.O  surge 28.3%
to $15.88 in morning trade  
    ** Co says its experimental drug, rosnilimab, met the main
goal in a mid-stage trial for the treatment of rheumatoid
arthritis, a chronic inflammatory disease that primarily affects
the joints 
    ** The main goal was to evaluate if the drug could
significantly reduce symptoms in three dosages using a tool
called DAS-28 CRP score, which measures the severity of the
disease after 12 weeks in comparison with placebo  
     ** ANAB says that the drug will be tested in patients with
a type of bowel disease called ulcerative colitis by the second
quarter of this year      
    ** Stock fell 46% in the last 12 months 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))